Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981473 · ClinicalTrials.gov registry record
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 605
- Enrollment target
NCT01981473: Completed study, sponsored by Pfizer.
NCT01981473 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 605 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01981473 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 605 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
Primary Outcome
Percentage of participants positive for antidrug antibodies among those treated with etanercept versus those treated with monoclonal antibodies (adalimumab or infliximab) was determined.
Interventions
- OTHER no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
What the finished NCT01981473 record still lists
NCT01981473 is an observational study that tracks outcomes without assigning an intervention. The registered 605 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which no intervention is the first listed.
NCT01981473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01981473 about?
NCT01981473 is a clinical study titled "Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab". The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
What is the current status of trial NCT01981473?
This trial is currently completed. The enrollment target is 605 participants. The study started on 2014-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01981473?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT01981473?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia